The content on this site is intended for healthcare professionals only
Selecting appropriate first line lung cancer therapy
Published: 8 Jul 2009
Views: 15791
Dr Paul Bunn - University of Colorado, Denver, USA
erlotininb, cetuximab or gefitinib for lung cancer in pill form- less toxic and better tolerated, better survival for patients with EGFR gene mutation.
- Categories:
- Lung & pleura
- Biology
- Targeted molecules
Related Videos
ASCO 2022: Latest in EGFR positive NSCLC
Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip
5 Jun 2022
Latest in testing and diagnostics in exon 20 NSCLC
Dr Antonio Passaro and Prof Paul Hofman
4 Jun 2022
Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for rese...
Prof Nicolas Girard - Institut Curie, Paris, France
10 May 2022
Recent advances in the treatment of patients with exon 20 insertion-positive NSC...
Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl
21 Apr 2022
EGFR testing: Best practice for NSCLC patients with exon 20 insertions
Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari
30 Mar 2022
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
23 Sep 2021
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity
Dr Danny Nguyen - City of Hope, Orange County, USA
21 Sep 2021
Oncogenesis: Lung cancer
Dr Edgardo Santos - Florida Precision Oncology, GenesisCare, Florida, USA
28 Jul 2021
Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC a...
Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China
16 Jul 2021